Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives by Femminella, GD et al.
Review Article
Antidiabetic Drugs in Alzheimer’s Disease: Mechanisms of
Action and Future Perspectives
Grazia Daniela Femminella,1 Leonardo Bencivenga,2 Laura Petraglia,2 Lucia Visaggi,2
Lucia Gioia,2 Fabrizio Vincenzo Grieco,2 Claudio de Lucia,2,3 Klara Komici,2
Graziamaria Corbi,4 Paul Edison,1 Giuseppe Rengo,2,5 and Nicola Ferrara2
1Neurology Imaging Unit, Imperial College London, London, UK
2Division of Geriatrics, Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy
3Center for Translational Medicine and Department of Pharmacology, Lewis Katz School of Medicine, Temple University,
Philadelphia, PA, USA
4Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
5Istituti Clinici Scientiﬁci Maugeri SpA Società Beneﬁt, Telese Terme Institute (BN), Italy
Correspondence should be addressed to Nicola Ferrara; nicferra@unina.it
Received 10 March 2017; Accepted 7 May 2017; Published 31 May 2017
Academic Editor: Soledad Ballesteros
Copyright © 2017 Grazia Daniela Femminella et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
is properly cited.
Diabetes mellitus (DM) and Alzheimer’s disease (AD) are two highly prevalent conditions in the elderly population and major
public health burden. In the past decades, a pathophysiological link between DM and AD has emerged and central nervous
system insulin resistance might play a signiﬁcant role as a common mechanism; however, other factors such as inﬂammation
and oxidative stress seem to contribute to the shared pathophysiological link. Both preclinical and clinical studies have evaluated
the possible neuroprotective mechanisms of diﬀerent classes of antidiabetic medications in AD, with some promising results.
Here, we review the evidence on the mechanisms of action of antidiabetic drugs and their potential use in AD.
1. Introduction
Diabetes mellitus (DM) represents a major public health bur-
den and a growing prevalent chronic disease. It is known that
more than 400 million have diabetes, and it is estimated that
the number of diabetic patients is expected to rise to over 640
million by 2040 [1]. Alzheimer’s disease (AD) is the main
cause of dementia, aﬀecting over 26 million people world-
wide [2], and its prevalence continues to increase [3]. Both
conditions are related to age, and in the last decades, an inter-
esting link between the two diseases has emerged from vari-
ous studies [4, 5]; thus, the term “type 3 diabetes” has been
proposed to deﬁne insulin resistance-induced AD [6]. Many
epidemiological evidence show an almost doubled risk for
AD in diabetic patients, compared with nondiabetics [7];
the Rotterdam study showed a twofold increase of AD in
DM and an even quadrupled risk associated with insulin
therapy [8]. Although the pathophysiological connections
are still not fully elucidated, two main key points have been
identiﬁed to explain this association: insulin resistance and
inﬂammatory signalling pathways [9].
2. DM and AD: Shared Pathophysiological
Components
Hyperinsulinemia and insulin resistance, two of the hall-
marks of type II DM (T2DM), have been shown to be impor-
tant risk factors for elderly cognitive decline [10]. Indeed,
while an acute administration of insulin may improve mem-
ory domains, dysfunctions in delayed memory process can
result from chronic administration [9]. Insulin signalling
induces brain to take up glucose and to produce insulin-
degrading enzyme (IDE), in order to reduce its level. IDE is
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involved in both insulin and amyloid beta (Aβ) degradation;
thus, hyperinsulinemiamight determine a competitive inhibi-
tion for IDE-dependent Aβ degradation, leading to Aβ accu-
mulation [11]. Moreover, in diabetes, alteration of insulin
signalling determines less IDE production, resulting in reduc-
tion of Aβ degradation; the process deﬁnitely leads to abnor-
mal Aβ accumulation in the brain. Therefore, increasing
insulin signalling in the brain might reduce Aβ accumulation.
Insulin has also been reported to enhance Aβ clearance from
the brain [12]. Furthermore, soluble Aβ oligomers, known as
amyloid beta-derived diﬀusible ligands (ADDLs), contribute
to insulin resistance in AD by modifying synapse conforma-
tion. This altered shape conformation is responsible for
reduced aﬃnity of synaptic insulin receptor for its ligand [9].
Moreover, abnormal protein processing characterizes
many neurodegenerative disorders. In particular, deposition
of extracellular Aβ plaques appears to be exacerbated by
impaired insulin signalling function in AD [13]; abnormal
Aβ induces hyperphosphorylation of the tau protein, the
major component of intracellular neuroﬁbrillary tangles
(NFT) [14]. These altered pathways involve glycogen syn-
thase kinase-3 (GSK-3), the enzyme that phosphorylates tau
to create AD neuroﬁbrillary tangles, which has been shown
to be downregulated in response to insulin [15]. Neuropa-
thology of AD is characterized by loss of synapses, while
insulin receptor signalling increases synaptic density. Inter-
estingly, impairment of insulin signalling seems to precede
Aβ accumulation in a transgenic mouse model of AD [16].
Furthermore, tau gets phosphorylated by c-Jun NH2-termi-
nal kinase (JNK), which is activated by chronic hyperglycae-
mia and regulated by JNK-interacting protein 1, also known
as “islet brain 1 protein” for its brain and pancreatic islet
expression [17].
Both T2DM and AD are largely related to inﬂammatory
processes. Insulin resistance is associated with elevated levels
of proinﬂammatory cytokines such as C-reactive protein,
tumor necrosis factor- (TNF-) α, interleukin- (IL-) 1, and
IL-6 [18]. All these cytokines are considered an indirect sign
of the immunological dysfunction that leads to insulin
resistance [19]. Likewise, IL-6 and C-reactive protein are
connected to Aβ plaque deposition and progression, and on
the other side, a reduced AD incidence has been reported
in patients under chronic nonsteroidal anti-inﬂammatory
therapy [4]. Another relevant aspect is represented by the
proinﬂammatory role of astrocytes and microglia surround-
ing Aβ plaques, that are responsible of neuronal irreversible
damage as a consequence of complement cascade activation
[20]. Interestingly, insulin seems to have anti-inﬂammatory
eﬀects directly suppressing proinﬂammatory cytokines and
inducing anti-inﬂammatory mediators, as demonstrated in
both preclinical and clinical studies [21].
Central obesity, deﬁned as both high body mass index
and mean waist circumference, represents a well-known risk
factor for the development of insulin resistance, through an
increased inﬂammatory response that alters insulin receptor
signalling pathway. This may result in metabolic syndrome,
a disorder also characterized by dyslipidaemia and hyperten-
sion, frequently precursor of T2DM. The role of obesity in
promoting AD has been explored in many studies [22], and
although the underlying mechanisms of this interaction is
not yet known, AD risk is correlated with insulin resistance,
oxidative stress, advanced glycation end products (AGEs),
and hyperglycaemia. Furthermore, some evidence suggest
that leptin could be used as a biomarker, in order to improve
the understanding of AD risk and progression [23]. Epide-
miological data suggest that insulin resistance is associated
with increased risk of cognitive impairment [24], and PET
studies have demonstrated that greater insulin resistance is
associated with an AD-like pattern of reduced cerebral glu-
cose metabolic rate in frontal, parietotemporal, and cingu-
late regions in adults with T2DM [25]. Thus, it is not
surprising that insulin could be an eﬀective treatment for
AD by increasing neuronal glucose uptake and cellular
ATP levels [26].
Dyslipidaemia and hypercholesterolemia contribute to
the development of both DM and AD. Apolipoprotein E4
(APOE4), predominantly expressed in the liver and the
brain, is the major genetic risk factor for sporadic AD [27].
In particular, APOE4 is associated with an increase in Aβ
plaque deposition and susceptibility to oxidative stress [28],
compared to the other APOE isoforms. Furthermore, higher
rate of tau phosphorylation is induced by the overexpression
of APOE4 in transgenic mice [29], while hippocampal
expression of IDE is negatively correlated with APOE
isoform 4 [11].
AGEs are heterogeneous compounds deriving from sugar
irreversible nonenzymatic reactions with the protein amino
groups, nucleotides, and lipids. This process that normally
occurs during aging is accelerated in diabetic patients, due
to the increased formation of reactive oxygen species. At this
regard, Sasaki and collaborators have described an enhanced
AGE immunoreactivity also in AD patients, particularly in
Aβ plaques and NFT of hippocampal neurons [30].
The abovementioned overproduction of reactive oxygen
species and the general increase in oxidative stress are char-
acteristics of DM. Oxidized protein accumulation has also
been demonstrated in the hippocampus, frontal and tempo-
ral lobes of mild cognitive impairment patients, suggesting
an early impact of oxidative damage in AD development
[14]. Mitochondria seem to play a pivotal role in this process
as suggested by Moreira and colleagues, who have identiﬁed
an involvement of mitochondrial dysfunction (oxidative
phosphorylation uncoupling and respiratory chain alteration)
in the development of neural degeneration and uncontrolled
metabolism in rat model of T2DM [31].
3. Classes of Antidiabetic Drugs as Potential
Treatments for Alzheimer’s Disease
Given the multiple links between DM and AD, it is not sur-
prising that several drugs currently approved for DM could
also have a role in treating AD [32]. Diﬀerent studies have
explored the possible neuroprotective mechanisms of antidi-
abetic medications, and some of them have also been tested
in clinical trials in AD and mild cognitive impairment
(MCI) subjects. Here, we summarize some of the evidence
from preclinical and clinical studies.
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3.1. Insulin. Preclinical studies have shown that in the rat
model of intracerebroventricular streptozotocin (STZ)
injection-induced cognitive dysfunction, the intraventricular
administration of detemir, a long-acting insulin analog,
rescued STZ-induced cognitive decline, as evidenced by a
signiﬁcant elevation in learning ability. Moreover, detemir
treatment resulted in changes in hippocampal levels of insu-
lin receptor [33]. Early clinical studies have indicated that
hyperinsulinemia without hyperglycaemia enhances mem-
ory in adults with AD, suggesting an important role of this
hormone in memory facilitation [34]. However, the systemic
administration of insulin is associated with increased risk of
hypoglycemia and reduced penetration in the central ner-
vous system (CNS). To overcome these issues, intranasal
administration of insulin has been tested in several studies,
proving to be eﬀective in directly targeting the brain [35].
Preclinical evidence indicated that insulin administered
intranasally bypasses the blood-brain barrier (BBB), and
human studies have shown that following intranasal admin-
istration, a signiﬁcant amount of insulin reaches the brain in
a functionally active state [36].
In healthy volunteers, the intranasal administration of
insulin (4× 40 IU/d) for 8 weeks resulted in a signiﬁcant
improvement in delayed word recall tests and enhanced
mood [37]. In a comparative study between regular human
insulin and the rapid-acting insulin analog insulin aspart, it
has been demonstrated that after 8 weeks of intranasal treat-
ment, memory performance measured by word list recall was
improved compared to placebo in both the aspart and the
regular insulin groups. The aspart-treated subjects per-
formed even better than those of the regular insulin-treated
group [38]. Similar ﬁndings were observed in a group of
obese subjects treated with intranasal insulin for 8 weeks:
insulin treatment did not induce any signiﬁcant reduction
of body weight but declarative memory and mood were
improved [39]. Insulin is also able to increase regional cere-
bral blood ﬂow in the insular cortex and the putamen in
healthy volunteers [40].
In patients with early AD and MCI, acute intranasal
administration of 20 or 40 IU of insulin facilitated verbal
memory recall especially in APOE4− subjects. Interestingly,
memory-impaired APOE4+ subjects showed poorer recall
following insulin administration, suggesting that APOE
might have a role in mediating insulin eﬀects in the CNS
[41]. Further studies from the same group have also demon-
strated that 21 days of intranasal insulin were able to improve
attention, verbal memory, and functional status in AD and
MCI subjects and to raise plasma concentrations of the short
form of the beta-amyloid peptide, resulting in an increased
Aβ 40/42 ratio [42]. The eﬀects of insulin on cognition are
dose-dependent, with maximal eﬀect at 20UI, and modu-
lated by APOE genotype [43]. These data prompted the ﬁrst
pilot trial with intranasal insulin in 104 patients with AD and
MCI. Treatment with 20 or 40 IU of insulin improved cogni-
tion and functional ability compared to placebo, as measured
by ADAS-cog and ADCS-ADL, respectively. Moreover, cere-
bral 18F-ﬂuorodeoxyglucose (18F-FDG) uptake signiﬁcantly
worsened at 4 months in placebo-treated group, while no
changes in CSF biomarkers were observed [44]. Recently,
the long-lasting insulin detemir has been tested for intra-
nasal administration in AD and MCI, showing a treatment
eﬀect for the memory composite outcome compared with
placebo. Similar to previous studies, this eﬀect was moder-
ated by the APOE status [45]. These preliminary data have
prompted larger double-blinded placebo-controlled trials
of insulin in AD. Two are ongoing in the US at the moment
and are expected to complete recruitment in 2017
(NCT01767909; NCT02503501).
3.2. Metformin.Metformin is a biguanide that increases insu-
lin sensitivity in peripheral tissues and suppresses hepatic
gluconeogenesis. The evidence for its use in AD are contro-
versial. Preclinical data suggest that orally administered met-
formin rapidly crosses the BBB and accumulates in CNS
structures at diﬀerent levels [46]. In vitro experiments on
neuronal cell lines under prolonged hyperinsulinemic condi-
tions have shown that treatment with metformin was able to
resensitize insulin signalling and prevent the molecular and
pathological changes observed in AD neurons [47]. More-
over, in murine primary neurons from wild type and tau
transgenic mice, metformin treatment was able to reduce
tau phosphorylation, one of the pathological hallmarks of
AD [48]. In a murine model of leptin-resistant obese mice,
systemic administration ofmetformin attenuated the increase
of total tau and phospho-tau in the hippocampus but had no
signiﬁcant eﬀects on tests of spatial learning and memory
[49]. A population-based case-control study evaluating the
incident risk of AD in diabetic patients on diﬀerent antidia-
betic medications suggested that overall the long-term use of
sulfonylureas, thiazolidinediones, or insulin was not associ-
ated with an altered risk of developing AD. However, a slight
increase of AD was reported in chronically metformin-
treated patients [50]. Similarly, another study has reported
that in patients with diabetes, use ofmetforminwas associated
with worse cognitive performance that could be attenuated by
coadministration of vitamin B12 and calcium supplements
[51]. Recently, the results of a 12-month pilot trial of metfor-
min in 80 patients with MCI have shown that compared to
placebo, signiﬁcant changes were observed in verbal memory
scores. Brain glucose uptake or plasma amyloid levels did not
show signiﬁcant diﬀerences in the two groups [52].
3.3. Thiazolidinediones. These drugs are agonists of the per-
oxisome proliferator-activated receptor-gamma (PPARγ).
In DM, they reduce serum glucose levels in response to insu-
lin; moreover, they improve insulin resistance and ameliorate
cholesterol homeostasis [53]. Currently, only pioglitazone is
approved in DM therapy, while rosiglitazone has been
withdrawn from the market due to high incidence of cardio-
vascular events. Both rosiglitazone and pioglitazone have
been tested as potential treatment in AD, with inconclusive
results. The potential for their use in AD derives from evi-
dence showing an increased expression of PPARγ in AD
temporal cortex compared to controls [54]. Moreover, in
preclinical studies, PPARγ agonists have been shown to
ameliorate AD-related pathology, probably reducing the
expression of inﬂammatory genes and decreasing amyloid
plaque burden [55]. Moreover, they seem to exhibit
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neuroprotective eﬀects modulating calcium homeostasis in
the hippocampus [56]. An early pilot study with rosiglitazone
in AD andMCI patients demonstrated that 6months of treat-
ment were able to improve delayed recall and attention
compared to placebo [57]. A larger study with three diﬀerent
doses of rosiglitazone (2, 4, or 8mg for 6months) showed that
a signiﬁcant improvement in the primary endpoint (ADAS-
Cog change from baseline) was only observed in APOE4−
patients on 8mg [58]. However, larger phase III trials of
rosiglitazone in AD as adjunctive therapy to acetylcholine
esterase inhibitor (AChEI) failed to show any signiﬁcant
improvement in cognition or global function in patients strat-
iﬁed according to their APOE4 status [59].
Similarly, a pilot study with pioglitazone in AD patients
with DM indicated that 15–30mg of pioglitazone for 6
months improved cognition and cerebral blood ﬂow in the
parietal lobe compared to controls. Also, pioglitazone treat-
ment resulted in a decrease in fasting plasma insulin levels,
indicating enhanced insulin sensitivity [60]. Another pilot
trial assessing pioglitazone safety in patients with ADwithout
DM demonstrated that 18 months of treatment were well
tolerated by patients but no signiﬁcant data on eﬃcacy were
observed [61]. A recent metanalysis on PPARγ agonists in
AD suggests that only pioglitazone may oﬀer an improve-
ment in the early stages of AD and in mild-to-moderate
AD [62]. Recently, it has been announced that the TOMOR-
ROW clinical trial, assessing the eﬃcacy of 24 months of pio-
glitazone treatment in patients with MCI (NCT1931566), has
completed its recruitment of 3500 subjects. The trial is also
investigating a genetic-based biomarker risk assignment
algorithm that comprises three components: APOE status,
translocase of outer mitochondrial membrane (TOMM40)
genotypes, and age. Its results will be available in 2019.
3.4. Glucagon-Like Peptide Receptor Agonists and Dipeptidyl
Peptidase-4 Inhibitors. Glucagon-like peptide-1 (GLP-1) is a
peptide hormone belonging to the incretin family, and it is
secreted by the intestine in response to food intake. Its recep-
tors (GLP-1Rs) can be found on pancreatic β-cells and, in
response to high glucose levels, promote insulin release. Once
secreted, native GLP-1 is degraded within minutes by the
enzyme dipeptidyl peptidase-4 (DPP4); therefore, GLP-1
analogs that are resistant to DPP4 action have been devel-
oped for clinical use. These GLP1-R agonists (exendin-4,
liraglutide, and lixisenatide) have been approved for treat-
ment of DM [63]. However, GLP-1Rs are also present in
the CNS, especially in the hypothalamus, hippocampus, cere-
bral cortex, and olfactory bulb [64]. GLP-1 seems to have
several favorable eﬀects within the CNS, where activation of
GLP-1Rs protects against apoptosis, is neuroprotective
against diﬀerent stimuli, and induces neurite outgrowth,
particularly in the hippocampus [65]. Several preclinical
studies have tested the potential neuroprotective eﬀects of
GLP-1 analogs in AD, with promising results. Systemic
administration of liraglutide for 8 weeks in AD transgenic
mice prevented memory impairment, neuronal loss, and
deterioration of synaptic plasticity in the hippocampus.
Moreover, litaglutide was able to reduce amyloid plaque
deposition by 40–50%, and reduce inﬂammatory response,
as measured by activated microglial cells [66]. Similarly, in
rats treated with intrahippocampal injection of Aβ, pretreat-
ment with liraglutide signiﬁcantly protected against the Aβ-
induced impairment of spatial memory and long-term
potentiation [67]. Further preclinical studies have demon-
strated that liraglutide promotes neurogenesis, reduces tau
hyperphosphorylation, and is also able to exert beneﬁcial
eﬀects on cerebral and systemic microvasculature in AD
transgenic mice [68–70]. Importantly, liraglutide does not
only have preventive properties but can also reverse some
of the key pathological hallmarks of late-stage AD in mice
[71]. A pilot clinical trial testing liraglutide in AD patients
has demonstrated that 6-month treatment with this GLP-1
analog was able to prevent decline of brain glucose
metabolism, although no signiﬁcant cognitive changes were
observed compared to the placebo group [72]. A larger trial
(ELAD) is currently ongoing at the Imperial College London,
evaluating liraglutide in a large group of AD patients
(NCT01843075). Among the other GLP-1 analogs, also, exe-
natide has shown promising results for its use in neurodegen-
erativediseases inpreclinical studies [73], andaclinical trial on
early-stage Alzheimer’s disease or mild cognitive impairment
is expected to publish their results soon (NCT01255163).
The inhibitors of DPP4, or gliptins, stabilize GLP-1 levels
by inhibiting its degradation and lower fasting and postpran-
dial glucose. Saxagliptin and vildagliptin have been approved
in DM and have also been tested in preclinical studies of
STZ-induced AD. Oral administration of both saxagliptin
and vildagliptin resulted in attenuation of Aβ deposition,
tau phosphorylation, and inﬂammatory markers and an
improvement in hippocampal GLP-1 levels and memory
retention [74, 75]. No clinical data are currently available
for the potential eﬀects of gliptins in AD patients.
3.5. Amylin Analog. Amylin is a small peptide hormone that
is cosecreted with insulin from pancreatic β-cells in response
to nutrient intake. It shares several features with Aβ, includ-
ing similar β-sheet structure and being degraded by the
insulin-degrading enzyme [76]. Amylin can cross the BBB
and seems to have a role in the regulation of memory, mood,
and anxiety [35]. However, because of its amyloidogenic
potential, its analog pramlintide has been approved by the
FDA, for use in DM type 1 and type 2. In AD patients, amylin
plasma levels are signiﬁcantly reduced and preclinical data in
mouse models of AD suggest that pramlintide administration
might improve memory, decrease oxidative stress, and
reduce neuroinﬂammation [77]. Further studies are needed
to assess the potential role of amylin and its analog in AD.
4. Conclusions
Of over 400 trials performed in AD from 2002 to 2012, only
one has led to the approval of a medication (memantine in
2003) for its clinical use in AD, proving that drug develop-
ment in AD is indeed very diﬃcult [78]. Disappointing
results have also been reported by the failure of antiamyloid
strategies, suggesting that other pathways need to be explored
in the search of disease-modifying agents in AD. The patho-
physiological links between AD and DM and the availability
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of several antidiabetic drugs that have already shown in pre-
clinical studies a potential beneﬁcial eﬀect onmultiple aspects
of neurodegeneration certainly suggest that these medica-
tions need further evaluation in AD. Encouraging results have
been obtained by multiple clinical trials of intranasal insulin
administration in AD, with no major side eﬀects, making
insulin a promising treatment in AD. Currently, several trials
with antidiabetic drugs in AD and MCI are underway and
their results are expected in the next few years. Besides, fur-
ther studies exploring the molecular mechanisms underlying
the favorable eﬀects of antidiabetic drugs in the CNS could
open new perspectives on future treatments.
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